Entera Bio Ltd has a consensus price target of $8, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 2, 2024, December 11, 2023, and September 13, 2023. With an average price target of $10 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 395.05% upside for Entera Bio Ltd from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Entera Bio (NASDAQ: ENTX) was reported by HC Wainwright & Co. on April 2, 2024. The analyst firm set a price target for $10.00 expecting ENTX to rise to within 12 months (a possible 395.05% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Entera Bio (NASDAQ: ENTX) was provided by HC Wainwright & Co., and Entera Bio maintained their buy rating.
There is no last upgrade for Entera Bio.
There is no last downgrade for Entera Bio.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Entera Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Entera Bio was filed on April 2, 2024 so you should expect the next rating to be made available sometime around April 2, 2025.
While ratings are subjective and will change, the latest Entera Bio (ENTX) rating was a maintained with a price target of $10.00 to $10.00. The current price Entera Bio (ENTX) is trading at is $2.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.